Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461097 · ClinicalTrials.gov registry record · Phase 2
Oral Immunotherapy for Childhood Egg Allergy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00461097 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 55 participants.
The verdict
NCT00461097, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.
Interventions
- DRUG Egg oral immunotherapy
- DRUG Control Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461097
The ClinicalTrials.gov registry entry for NCT00461097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Egg oral immunotherapy is the first listed.
NCT00461097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461097 about?
NCT00461097 is a clinical study titled "Oral Immunotherapy for Childhood Egg Allergy". The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.
What is the current status of trial NCT00461097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2007-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00461097?
The interventions under investigation include: Egg oral immunotherapy (DRUG), Control Group (DRUG).
Who is sponsoring clinical trial NCT00461097?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.